Información del artículo
El Texto completo está disponible en PDF
Bibliogrífia
[1.]
G. Fattovich, G. Giustina, F. Degos, et al.
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients.
Gastroenterology, 112 (1997), pp. 463-472
[2.]
R. Idilman, N. De Maria, A. Colantoni, et al.
Interferon treatment of cirrhotic patients with chronic hepatitis C.
J Viral Hepatitis, 4 (1997), pp. 81-91
[3.]
D.C. Valla, M. Chevallier, P. Marcellin, et al.
Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa 2b versus no treatment.
Hepatology, 29 (1999), pp. 1870-1875
[4.]
Y. Shiratori, O. Yokosuka, R. Nakata, et al.
Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis CRNA.
Hepatology, 29 (1999), pp. 1573-1580
[5.]
J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Shiftman, W.M. Lee, V.K. Rutsgi, et al.
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.
N Engl J Med, 339 (1998), pp. 1485-1492
[6.]
T. Poynard, P. Marcellin, S.S. Lee, C. Niederau, G.S. Minuk, G. Ideo, et al.
Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus.
Lancet, 352 (1998), pp. 1426-1432
[7.]
S.W. Schalm, O. Weiland, B.E. Hansen, et al.
Interferon. Ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data for six controlled trials.
Gastroenterology, 117 (1999), pp. 408-431
[8.]
E.J. Heathcote, M.L. Schiffman, G.E. Cooksley, et al.
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
N Engl J Med, 343 (2000), pp. 1673-1680
[9.]
M.P. Manns, J.G. McHutchison, S. Gordon, et al.
Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Lancet, 358 (2001), pp. 958-965
[10.]
H.L. Janssen, J.T. Brouwer, F. Nevens, J.M. Sanchez-Tapias, A. Craxi, S. Hadziyannis.
Fatal hepatic decompensation associated with interferon alfa. European concerted action on viral hepatitis.
BMJ, 306 (1993), pp. 107-108
[11.]
M. Prieto, M. Berenguer, J.M. Rayon, J. Cordoba, L. Arguello, D. Carrasco, et al.
High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.
Hepatology, 29 (1999), pp. 250-256
[12.]
A. Halprin, J.F. Trotter, G. Everson, M. Wachs, T. Bak, M. Kugelmas, et al.
Post-transplant eradication of hepatitis C by pre-transplant treatment in living donor liver transplant recipients [abstract].
Hepatology, 34 (2001), pp. 244A
[13.]
S. Agrawal, S. Mehta, J. Daly, H.L. Bonkovsky, E. Katz, M. Halvorsen, et al.
Treatment of chronic hepatitis C with interferonalfa 2b and ribavirin in decompensated cirrhotics listed for transplant [abstract]. A retrospective study.
Hepatology, 34 (2001), pp. 322A
[14.]
S. Nishiguchi, T. Kuroki, S. Nakatani, et al.
Randomised trial of effects of interferon-alfa on incidence of hepatocellular carcinoma in chronic active hepatitis C and cirrhosis.
Lancet, 346 (1995), pp. 1051-1055
[15.]
L. Serfaty, H. Aumaitre, O. Chazouilleres, A.M. Bonnand, O. Rosmorduc, R.E. Poupon, et al.
Determinants of outcome of compensated hepatitis C virus-related cirrhosis.
Hepatology, 27 (1998), pp. 1435-1440
[16.]
J. Bruix, M. Sheman, J.M. Llovet, M. Beaugrand, R. Lencioni, A.K. Burroughs, et al.
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference.
J Hepatology, 35 (2001), pp. 421-430
Copyright © 2002. Elsevier España, S.L.. Todos los derechos reservados
